The concern of generic rivalry has repeatedly loomed above copyright’s iconic drug, Sildenafil, raising questions about the future of connected medicinal holdings. While early times saw substantial returns, the intellectual property lapse has created the path for less expensive copies, potentially lowering earnings and creating a real hazard for